Foundation Medicine Reports Preliminary 2016 Results
Achieves Total Revenue of Approximately
Reports 43,686 Clinical Tests in 2016, a 32% Year Over Year Increase
The company reported 12,788 clinical tests to ordering physicians in the fourth quarter of 2016, compared to a total of 8,286 tests reported during the fourth quarter of 2015. A total of 43,686 clinical tests were reported to ordering physicians for the full year ended December 31, 2016, compared to 32,998 clinical tests reported in 2015. Cash, cash equivalents and marketable securities at December 31, 2016, was approximately $143 million.
"Foundation Medicine evolved significantly in 2016, most notably through continued growth in clinical and biopharma product demand and utilization, product diversification through the launch of FoundationACT™ and the achievement of FoundationFocus™ CDxBRCA, our first
2016 Enterprise Highlights:
- Announced acceptance of FoundationOne for Parallel Review by
FDA and CMS. TheFDA also acceptedFoundation Medicine's request for review as part of its Expedited Access Pathway (EAP) for breakthrough devices. If approved, FoundationOne could be the firstFDA -approved comprehensive genomic profiling (CGP) assay to incorporate multiple companion diagnostics to support precision medicine in oncology and would be offered as a covered benefit toMedicare beneficiaries nationwide. - Launched FoundationACT, the company's ctDNA assay, to clinical customers. FoundationACT was developed with the same rigorous analytical validation standards as FoundationOne and FoundationOne Heme.
- Received FDA Approval of FoundationFocus CDxBRCA as a companion diagnostic for Rubraca™ (rucaparib) for the treatment of women with ovarian cancer. FoundationFocus is the first next generation sequencing companion diagnostic approved by the
FDA and marks important progress towards the development of the company's universal pan-cancer companion diagnostic assay. - Expanded patient access to CGP through Palmetto, a
Medicare administrative contractor inNorth Carolina , who broadened a Local Coverage Determination covering CGP for all stage IIIb and IV non-small cell lung cancer patients at diagnosis. - Added new immunotherapy clinical markers, Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI), to FoundationOne and FoundationOne Heme to help guide personalized, immunotherapy-based treatment plans.
- Grew biopharmaceutical revenue by approximately 79% in 2016 and added several new molecular information, SmartTrials™ and companion diagnostic collaborations.
- Increased FoundationCORE™, the company's molecular information database, to more than 100,000 clinical cases.
- Expanded the company's laboratory footprint to include sites at
Research Triangle Park (RTP) inNorth Carolina and Penzberg,Germany . The RTP facility became operational in September, increasing operational flexibility and broadening commercial opportunities. Once operational, the Penzberg location will support continued growth and expansion inEurope through our commercial collaboration withRoche . - Published 72 peer-reviewed manuscripts in top medical and scientific journals and presented 129 podium talks and posters at scientific and medical meetings.
2017 Outlook
As part of Foundation Medicine's commitment to being a partner for the patient journey, the company expects to advance a number of key business objectives in 2017. These include: advancing its universal, pan-cancer companion diagnostic assay through the
Complete 2016 fourth quarter and full year financial results will be announced during the company's fourth quarter and fiscal year 2016 financial results conference call in February. The company also anticipates providing 2017 financial guidance at that time. This press release contains certain unaudited financial results for the company. These unaudited results could change as a result of further review by the company's management and its independent auditors.
Dr. Pellini is scheduled to present at the 35th Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2017, at 9:00 a.m. PST, in San Francisco. A live, listen-only webcast of the presentation and breakout session may be accessed by visiting the investors section of the company's website at investors.foundationmedicine.com. A replay of the webcast will be available shortly after the conclusion of the presentation and breakout session and will be archived on the company's website for two weeks.
About
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the benefits of FoundationOne, FoundationOne Heme, FoundationACT and FoundationFocus CDxBRCA to physicians and patients in the treatment of cancer; the benefits provided by a FDA-approved version of FoundationOne; the scope and timing of any approval of FoundationOne as a medical device by the FDA and any coverage decision by CMS; strategies for achieving
View source version on businesswire.com: http://www.businesswire.com/news/home/20170109005425/en/
Media Contact:
dan@purecommunicationsinc.com
or
Investor Contact:
ir@foundationmedicine.com
Source:
News Provided by Acquire Media